Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15544
UPID:
TAF11_HUMAN
Alternative names:
TFIID subunit p30-beta; Transcription initiation factor TFIID 28 kDa subunit
Alternative UPACC:
Q15544; B2R8R3; B4DY18; Q9UHS0
Background:
The Transcription initiation factor TFIID subunit 11, also known as TFIID subunit p30-beta or the 28 kDa subunit, is integral to the TFIID basal transcription factor complex. This complex is pivotal in initiating RNA polymerase II-dependent transcription, recognizing and binding promoters with or without a TATA box through its TBP subunit. It facilitates the assembly of the pre-initiation complex, comprising TBP and various TBP-associated factors (TAFs), including TAF1 through TAF13, with TAF11 playing a crucial role in promoter binding.
Therapeutic significance:
Understanding the role of Transcription initiation factor TFIID subunit 11 could open doors to potential therapeutic strategies.